In the field of osteoporosis
Postmenopausal osteoporosis;
Chronic renal failure, especially renal osteodystrophy in patients undergoing hemodialysis;
Hypoparathyroidism following surgery;
Idiopathic hypoparathyroidism;
Pseudohypoparathyroidism;
Vitamin D-dependent rickets;
Hypophosphatemic vitamin D-resistant rickets, etc.
Idiopathic hypoparathyroidism;
The most common adverse reaction in clinical reports is hypercalcemia.
Possible adverse reactions are similar to those of vitamin D overdose, such as hypercalcemia syndrome or calcium intoxication (depending on the severity and duration of hypercalcemia). Occasional acute symptoms include decreased appetite, headache, nausea, vomiting, abdominal pain or upper abdominal pain, and constipation. Chronic symptoms include muscle weakness, weight loss, sensory disturbances, fever, thirst, polydipsia, polyuria, dehydration, emotional apathy, delayed development, and urinary tract infections.
Patients with concurrent hypercalcemia and hyperphosphatemia (concentration greater than 6mg/100ml or 1.9mmol/l) may experience calcium deposition.
Patients with sensitive constitution may experience allergic reactions including rash, erythema, itching and urticaria.
After 15 years of clinical use for all indications, the reported incidence of adverse reactions, including hypercalcemia, was very low, at 0.001% or lower.
This product is contraindicated in diseases related to hypercalcemia and in patients known to be allergic to the product, similar drugs, or any of their excipients;
It is also contraindicated in patients with signs of vitamin D intoxication.
Based in China and facing the world, HSN is a pharmaceutical group that provides integrated services of Commercialization, supply chain, and brand promotion of foreign high-end patented drugs in China. An emerging strategic partner for your brand.
Copyright © 2024 – Hesenna Medicine All rights reserved.
